Management of New-Onset Tic in a Child Taking Jornay (Methylphenidate)
Do Not Automatically Discontinue Jornay
Continue Jornay and monitor the tic closely, as methylphenidate does not cause or worsen tics in the majority of children, and the tic may be coincidental rather than medication-induced. 1, 2, 3
Evidence Supporting Continuation of Stimulant Therapy
Tics Are Common in Children With ADHD—With or Without Medication
- New-onset tics occur at similar rates in children treated with methylphenidate (5.7%) versus placebo (6.5%), with no statistically significant difference (risk ratio 0.99,95% CI 0.78–1.27). 1
- In a large randomized controlled trial, 20% of children on methylphenidate reported worsening tics as an adverse event, but this rate was no higher than in children receiving clonidine alone (26%) or placebo (22%). 2
- Clinically significant tics developed in 19.6% of children without preexisting tics on methylphenidate versus 16.7% on placebo (not statistically significant; relative risk 1.17,95% CI 0.31–4.40). 3
Methylphenidate May Actually Improve Tics in Some Children
- Measured tic severity lessened in children treated with methylphenidate alone, and even more so when methylphenidate was combined with clonidine. 2
- Methylphenidate appears to be the best-tolerated stimulant compound, with tics often lessening during treatment. 4
Guideline Recommendations Support Stimulant Use in Children With Tics
- Current guidelines state that controlled studies have not found that methylphenidate worsens motor tics in Tourette's syndrome, nor does it increase motor tics in children with ADHD without Tourette's. 5
- With proper informed consent, a trial of a stimulant can be undertaken in children with comorbid ADHD and tic disorder; if tics worsen markedly, the physician may move to an alternative stimulant or add an alpha-agonist such as clonidine or guanfacine. 5
Practical Management Algorithm
Step 1: Assess the Tic Severity and Timing
- Document the type, frequency, and severity of the tic using parent and teacher reports. 5
- Determine whether the tic appeared after starting Jornay or was present (but unnoticed) before medication initiation. 6
- If the tic is mild and not distressing to the child, continue Jornay and monitor weekly for 4–6 weeks, as the tic may resolve spontaneously. 1, 3
Step 2: If the Tic Is Moderate to Severe or Distressing
- Do not immediately discontinue Jornay; instead, consider reducing the dose by 25–50% and reassess in 1–2 weeks. 5
- If the tic improves with dose reduction but ADHD symptoms remain inadequately controlled, add guanfacine extended-release (starting at 1 mg nightly, titrating by 1 mg weekly to a target of 0.05–0.12 mg/kg/day) as adjunctive therapy. 5, 7
- Guanfacine is particularly appropriate when ADHD co-occurs with tics, as it treats both conditions without worsening tics and has an effect size of approximately 0.7 for ADHD symptoms. 5, 7
Step 3: If the Tic Persists or Worsens Despite Dose Reduction
- Switch to a different stimulant class (e.g., from methylphenidate to lisdexamfetamine or vice versa), as approximately 40% of patients respond to only one stimulant class. 5
- Data suggest that amphetamine-based stimulants may worsen tics more than methylphenidate, so methylphenidate should be tried first if not already used. 5
- If switching stimulants is ineffective or not tolerated, discontinue the stimulant and initiate atomoxetine (starting at 0.5 mg/kg/day, target 1.2 mg/kg/day) or guanfacine monotherapy. 5, 8
Step 4: If the Tic Resolves After Discontinuing Jornay
- Rechallenge with Jornay after 2–4 weeks, as the tic may have been coincidental rather than medication-induced. 1
- If the tic recurs upon rechallenge, confirm that Jornay is the cause and proceed to Step 3 (switch stimulant class or use non-stimulant). 1
Key Monitoring Parameters
- Obtain baseline tic severity using a standardized scale (e.g., Yale Global Tic Severity Scale) before starting or continuing Jornay. 5
- Monitor tic frequency and severity weekly during the first 6–8 months of treatment, as all tic aggravation with methylphenidate appears within approximately 8 months (or 6 months in children with a past history of tics). 6
- Assess ADHD symptom control using parent and teacher rating scales at each visit to ensure that tic management does not compromise ADHD treatment efficacy. 5
Common Pitfalls to Avoid
- Do not assume the tic is caused by Jornay without a trial of continued treatment or dose reduction, as tics are common in children with ADHD regardless of medication use. 1, 3
- Do not discontinue effective ADHD treatment solely due to a mild tic that is not distressing to the child, as untreated ADHD causes significant functional impairment. 5, 2
- Do not overlook the possibility that the tic may improve with continued methylphenidate treatment, as this has been observed in multiple controlled trials. 2, 4
- Do not use high-dose dextroamphetamine if tics are present, as one study suggested it may worsen tics more than methylphenidate. 5
When to Consider Non-Stimulant Alternatives as First-Line
- If the child has a past history of tics or Tourette's syndrome, guanfacine or atomoxetine may be preferred as first-line treatment to avoid any potential tic exacerbation. 5, 8
- Guanfacine is particularly appropriate when ADHD co-occurs with tics, sleep disorders, or oppositional symptoms, as it addresses all three conditions. 5, 7
- Atomoxetine is effective for both ADHD and tics, with a medium-range effect size of 0.7, and requires 6–12 weeks for full therapeutic effect. 5, 8
FDA-Approved Labeling on Tics
- The FDA label for methylphenidate states: "New or worsening tics or worsening Tourette's syndrome. Tell your healthcare provider if you or your child get any new or worsening tics or worsening Tourette's syndrome during treatment with Methylphenidate Hydrochloride Oral Solution." 9
- This warning reflects historical concerns rather than current evidence, as multiple randomized controlled trials have not supported an association between methylphenidate and tic worsening. 1, 2, 3